Research programme: small molecules antiviral therapeutics- ABIVAX/ Evotec

Drug Profile

Research programme: small molecules antiviral therapeutics- ABIVAX/ Evotec

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abivax; Evotec AG
  • Class Antivirals; Small molecules
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Dengue; Influenza virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 07 Sep 2017 Evotec AG and ABIVAX agree to co-develop small molecules antiviral therapeutics for Respiratory syncytial virus, Influenza and Dengue viral infections
  • 07 Sep 2017 Research in Dengue in Germany, France (unspecified route)
  • 07 Sep 2017 Research in Respiratory syncytial virus infections in France, Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top